High-throughput Reprogramming | Disease Models | AI-based Drug Discovery

At NYSCF, we collaborate with leading academic institutions and research centers, forward-thinking foundations, and innovative companies across the globe. Our partnerships take various forms to accelerate the path to successful future therapies. Leveraging NYSCF’s large-scale automation technology, these partnerships can encompass everything from the genesis of vital research resources, such as large iPSC cohorts for specific disease areas and in vitro human disease models, to developing and conducting high-throughput drug screening assays. Please see below for more info; we welcome your inquiries about these or other partnering opportunities.

High-throughput, automated generation of iPSC lines and derived cell types

NYSCF is a preferred partner for gold-standard, automated generation of iPSC lines and derived cell types. The NYSCF Global Stem Cell Array®, our cell culture automation technology, eliminates manual manipulations to reduce technical variability and maximize reproducibility. It has been the system of choice for academic, non-profit, government, and industry partners alikeThousands of unique iPSC lines from genetically diverse populations have been generated using our robotics and many are available through the NYSCF Repository. There are over 300 diseases represented in our repository as well as cell lines from healthy individuals. Recent partnering examples include: 

Collaborative disease modeling efforts

NYSCF’s expert scientific, technical, and clinical teams work together with leaders in the field to develop advanced human models of disease at population scale that capture patient heterogeneity, with the potential to transform traditional disease research and drug discovery. Examples of impactful, collaborative disease modeling projects include:

  • First iPSC model of PTSD reveals hypersensitivity of neurons to stress (Seah et al., Nature Neuroscience 2022)
  • Alzheimer’s hallmarks recapitulated in iPSC-neurons (Lagomarsino et al., Neuron 2021)
  • Unveiling drivers of genetic and idiopathic Parkinson’s Disease (read more)
  • Understanding genotype-phenotype relationships in type 2 diabetes, in collaboration with Dr. Francis Collins at NHGRI
  • Industry collaborations in iPSC-powered drug development for retinal, cardiac, neural, and rare diseases

These and many other projects leverage our proprietary platform and expertise to differentiate pluripotent stem cells into disease-relevant cell types, including neuronal, glial, pancreatic, cardiac, hepatic, retinal pigmented epithelial, cardiomyocytes, and immune cells. We have  established automated protocols for numerous cell types in 2D, allowing us to differentiate dozens or even hundreds of unique donor cell lines parallel, as well as select 3D cultures, including neural and pancreatic organoids. We have further instituted efficient methods for deriving cancer organoids from tumor resections to power precision medicine efforts in oncology, with an initial focus on ovarian cancer.

AI-based high-throughput screening of various therapeutic modalities

We combine high-throughput screening, artificial intelligence, and multi-modal assays to discover novel disease phenotypes, druggable targets, and therapeutic candidates. Our technology is capable of screening large libraries of small molecules and other therapeutics.

Read about our partnerships:

NYSCF and Google: Identifying novel cellular phenotypes of complex diseases, demonstrated in Parkinson’s patient fibroblasts, to enable target-agnostic drug screens

NYSCF and J&J: Using NYSCF’s AI-powered platform for drug discovery to target neurodegenerative disease

If you are interested in collaborative opportunities with NYSCF, please contact partnering@nyscf.org.